Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Prices IPO

NEW YORK (GenomeWeb News) – Cellular Dynamics International has priced its initial public offering at $12 per share, the stem cell technology firm announced late Wednesday.

Its shares are anticipated to trade on the Nasdaq under ticker symbol "ICEL." CDI is offering about 3.8 million shares in its IPO. Additionally it granted its underwriters a 30-day option to purchase an additional 576,900 shares.

JP Morgan Securities is the sole book-running manager on the offering. Cowen &Co and Leerking Swann are co-managers.

Proceeds will go toward R&D, sales and marketing, expansion of its sales force for commercialization of its products, building out of its laboratory, and working capital general corporate purposes.

CDI filed for its IPO last month.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more